Skip to main content
AMCP Nexus 2023 Main banner

Keynote

(K3) Oncology Pipeline: Shaping 2023 and Beyond

Thursday, October 19, 2023
10:00 AM – 11:15 AM East Coast USA Time
Location: Crystal H
CPE
ACPE UAN:0233-0000-23-067-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
This activity is supported by an independent medical education grant from Coherus BioSciences, Inc.

The cancer treatment pipeline has continually expanded over the past decade resulting in record-breaking numbers of approvals in the United States. Global spending on cancer medicine was $185 billion in 2021 and is expected to exceed $300 billion by 2026. Representing over one-third of drugs in the pipeline, oncology treatment continues to evolve and provide innovative treatment options. This session will cover key agents recently approved by the FDA or in late-stage development, focusing on novel mechanisms of action. The potential impact on current standards of care and the clinical and financial implications for payers regarding the emergence of these novel therapies will be discussed.

Learning Objectives::

At the completion of this activity, participants should be able to:
  1. Identify recently approved and upcoming approvals of high-impact oncology specialty drugs for solid and hematologic malignancies.
  2. Differentiate the mechanisms of action, indications, safety, and efficacy of newly approved and emerging oncology specialty medications.
  3. Assess the impact of new and emerging approvals of oncology specialty medications on cost considerations, contracting, benefit formularies, and other managed care processes.